Eisai Co Ltd (ESALF) 68.2800 $ESALF
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
According to analyst, Axovant's RVT-101 could be a blockbuster or maybe not
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 10:28AM CDT
AXON: 17.56 (-0.74), PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Partial Seizure - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f3bjg6/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/f3...al_seizure
MRNS: 13.62 (+1.72), CPRX: 4.88 (+0.20), PFE: 34.36 (+0.50), NVS: 103.22 (+3.20)
Hypersensitivity - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmmrm2/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Ensemble Therapeutics Corporation - F. Hoffmann-La Roche Ltd. - JW Pharmaceutical Corporation - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/km...ensitivity
ANAC: 84.61 (+1.95)
Rhabdomyosarcoma - Pipeline Review, H1 2015 - 8 Companies & 10 Drug Profiles
M2 - Fri Jun 12, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lcxsd2/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - Eisai Co., Ltd. - GlaxoSmithKline plc - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Novartis AG Drug Profiles - afatinib - Cell Therapy for GD2 Expressing Solid Tumors - celyvir - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - E-7438 - everolimus - irinotecan sucrosofate liposomal - NTX-010 - paclitaxel albumin bound - pazopanib hydrochloride For more information visit http://www.researchandmarkets.com/research/lc...myosarcoma
MACK: 12.08 (+0.43), BLCM: 19.58 (+0.74), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht3nzs/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - Amgen Inc. - AngioChem Inc. - Apogenix GmbH - AstraZeneca PLC - Axelar AB - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Celldex Therapeutics, Inc. - e-Therapeutics plc - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - ERC Belgium SA - GenSpera, Inc. - GlaxoSmithKline plc - GW Pharmaceuticals plc - ImmunoCellular Therapeutics, Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoEthix SA - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Sangamo BioSciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Tocagen Inc. - Vascular Biogenics Ltd. - Virttu Biologics Limited - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/ht3nzs/recurrent
ZIOP: 11.17 (+0.69), PFE: 34.36 (+0.50), CLDX: 24.89 (+0.42), SGMO: 9.86 (-0.02), AMGN: 154.10 (+2.79), SPPI: 7.08 (+0.05), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), IMUC: 0.49 (+0.01), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), VBLT: 6.19 (+0.32), KPTI: 25.57 (+0.24), NVS: 103.22 (+3.20)
Chagas Disease (American Trypanosomiasis) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 21 Drug Profiles
M2 - Wed Jun 10, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llmftq/chagas_disease) has announced the addition of the "Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Grupo Praxis Pharmaceutical SA - Merck & Co., Inc. - Panacela Labs, Inc. - Sanofi - Seek Drug Profiles - benznidazol - chagas disease vaccine - Cz-007 - Cz-008 - Drugs for Chagas Disease - E-1224 - EPLBS-1246 - EPLBS-967 - fexinidazole - K-777 - LH-7 - Monoclonal Antibody for Chagas - NEU-321 - posaconazole - Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Small Molecules for Chagas Disease - Small Molecules for Infectious Diseases - Small Molecules for Protozoal Infections - Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - VNI - XELRYX-3 For more information visit http://www.researchandmarkets.com/research/ll...as_disease
MRK: 57.95 (+0.57), ANAC: 84.61 (+1.95)
Chemotherapy Induced Peripheral Neuropathy Therapeutics Pipeline Review, H1 2015 - 12 Companies & 16 Drug Profiles
M2 - Tue Jun 09, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9fr24c/chemotherapy) has announced the addition of the "Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - DARA BioSciences, Inc. - Eisai Co., Ltd. - Immune Pharmaceuticals, Ltd. - Laboratorios Del Dr. Esteve S.A. - MAKScientific, LLC - Mertiva AB - Paladin Labs Inc. - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Spectrum Pharmaceuticals, Inc. - Spinifex Pharmaceuticals Pty Limited - Virobay Inc. Drug Profiles - (amitriptyline ketamine hydrochloride) - AK-295 - AL-309 - AM-1710 - E-2072 - E-52862 - EMA-401 - Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - KRN-5500 - LM11A-31 - PAN-811 - PGN-703 - Small Molecule for Chemotherapy Induced Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - SPI-205 - VBY-036 For more information visit http://www.researchandmarkets.com/research/9f...emotherapy
SPPI: 7.08 (+0.05), IMNP: 1.88 (+0.04), VBAY: ()
Functional (Non Ulcer) Dyspepsia Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxkxp9/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Eisai Co., Ltd. - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. - Rottapharm SpA - Zeria Pharmaceutical Co Ltd Drug Profiles - 5-BOIP - acotiamide hydrochloride - cinitapride - dexloxiglumide - IW-9179 - rabeprazole sodium DR - RQ-00000010 - RQ-00201894 For more information visit http://www.researchandmarkets.com/research/zx...tional_non
IRWD: 11.44 (-0.06)
Synovial Sarcoma Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hxq4ts/synovial_sarcoma) has announced the addition of the "Synovial Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adaptimmune Limited - Eisai Co., Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoTherapy Science, Inc. Drug Profiles - Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - E-7438 - everolimus - OTSA-101 - pembrolizumab - selinexor - SSTC-104 For more information visit http://www.researchandmarkets.com/research/hx...al_sarcoma
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Down Syndrome Pipeline Review, H1 2015 - 5 Companies & 12 Drug Profiles
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5gmd6/down_syndrome) has announced the addition of the "Down Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - NeuroNascent, Inc. - Transition Therapeutics Inc. Drug Profiles - ACI-24 - APH-1104 - AVL-8168 - BTD-001 - donepezil hydrochloride - ELND-005 - minocycline - NNI-351 - RG-1662 - Small Molecule DYRK1A Inhibitor for CNS Diseases - Small Molecules for Down Syndrome - Small Molecules to Inhibit OLIG2 for Down Syndrome For more information visit http://www.researchandmarkets.com/research/t5...n_syndrome
TTHI: 2.04 (+0.09)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 69.27 (+1.38), RGDO: 1.21 (unch)
Global Papillary Thyroid Cancer Therapeutics Pipeline Review, H1 2015 - 8 Companies & 13 Drug Profiles
M2 - Fri Jun 05, 6:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbchgs/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eisai Co., Ltd. - Exelixis, Inc. - Ignyta, Inc. - Novartis AG - Pfizer Inc. - Plexxikon Inc. - Vaccinex, Inc. Drug Profiles - cabozantinib s-malate - CLM-29 - CLM-3 - dabrafenib mesylate - entrectinib - everolimus - lenvatinib - pasireotide - PLX-7486 - PLX-8394 - sunitinib malate - vandetanib - VX-15 For more information visit http://www.researchandmarkets.com/research/fb...ry_thyroid
RXDX: 15.42 (+0.25), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Pipeline Review, H1 2015 - 14 Companies & 16 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lkxhm/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Azano Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eisai Co., Ltd. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Pfizer Inc. - PhytoHealth Corporation - Rigel Pharmaceuticals, Inc. - SuppreMol GmbH Drug Profiles - Antibody for Autoimmune Disorders and Inflammation - avatrombopag - AZ-175 - belimumab - BI-655064 - blisibimod - BMS-986004 - eltrombopag olamine - fostamatinib disodium - GL-2045 - GSK-2285921 - HL-161 - MK-8723 - PHN-013 - SM-101 - veltuzumab For more information visit http://www.researchandmarkets.com/research/7lkxhm/idiopathic
IMMU: 4.20 (+0.24), ANTH: 8.32 (+0.85), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), RIGL: 3.11 (+0.10), MNTA: 21.76 (+0.49)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 23.42 (+0.45), CTIC: 1.91 (+0.03), ABBV: 69.23 (+1.26), EXEL: 3.68 (+0.25), MGNX: 38.85 (+3.03), INCY: 108.33 (+0.22), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ATNM: 2.41 (+0.18), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), CALA: 6.77 (unch), AVEO: 1.57 (unch), AGIO: 109.82 (+2.33), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Global Peripheral T-Cell Lymphomas (PTCL) Pipeline Review 2015
M2 - Wed Jun 03, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d57tr7/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Affimed Therapeutics AG - Bayer AG - Celgene Corporation - Eisai Co., Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - Mundipharma International Limited - Onxeo SA - Sanofi - Solasia Pharma K.K. - Spectrum Pharmaceuticals, Inc. - TG Therapeutics, Inc. Drug Profiles - AFM-13 - alemtuzumab - alisertib - belinostat - copanlisib - darinaparsin - denileukin diftitox - forodesine hydrochloride - lenalidomide - masitinib - mogamulizumab - pralatrexate - romidepsin - ruxolitinib phosphate - selinexor - SH-7129 - TGR-1202 For more information visit http://www.researchandmarkets.com/research/d5...eral_tcell
INCY: 108.33 (+0.22), TGTX: 18.21 (+0.08), SPPI: 7.08 (+0.05), KPTI: 25.57 (+0.24), CELGZ: 2.15 (+0.14)
Arterial Thrombosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/24q755/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Arterial Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arterial Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - Sanofi Drug Profiles - AS-1468240 - ASP-1645 - ASP-6537 - BAY-1213790 - BMS-593214 - C-3 - E-5539 - ER-410660 - Ichorcumab - PZ-128 - SAR-216471 - Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - temanogrel hydrochloride - ticagrelor For more information visit http://www.researchandmarkets.com/research/24q755/arterial
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38), ARNA: 4.29 (+0.04)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 4.20 (+0.24), PFE: 34.36 (+0.50), INCY: 108.33 (+0.22), AZN: 66.45 (+1.90), AVEO: 1.57 (unch), AMGN: 154.10 (+2.79)
According to analyst, Axovant's RVT-101 could be a blockbuster or maybe not
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 10:28AM CDT
AXON: 17.56 (-0.74), PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Partial Seizure - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f3bjg6/partial_seizure) has announced the addition of the "Partial Seizure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - Marinus Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. For more information visit http://www.researchandmarkets.com/research/f3...al_seizure
MRNS: 13.62 (+1.72), CPRX: 4.88 (+0.20), PFE: 34.36 (+0.50), NVS: 103.22 (+3.20)
Hypersensitivity - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmmrm2/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Ensemble Therapeutics Corporation - F. Hoffmann-La Roche Ltd. - JW Pharmaceutical Corporation - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/km...ensitivity
ANAC: 84.61 (+1.95)
Rhabdomyosarcoma - Pipeline Review, H1 2015 - 8 Companies & 10 Drug Profiles
M2 - Fri Jun 12, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lcxsd2/rhabdomyosarcoma) has announced the addition of the "Rhabdomyosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - Eisai Co., Ltd. - GlaxoSmithKline plc - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Novartis AG Drug Profiles - afatinib - Cell Therapy for GD2 Expressing Solid Tumors - celyvir - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - E-7438 - everolimus - irinotecan sucrosofate liposomal - NTX-010 - paclitaxel albumin bound - pazopanib hydrochloride For more information visit http://www.researchandmarkets.com/research/lc...myosarcoma
MACK: 12.08 (+0.43), BLCM: 19.58 (+0.74), GSK: 42.45 (+0.65), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Recurrent Glioblastoma Multiforme (GBM) Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht3nzs/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - Amgen Inc. - AngioChem Inc. - Apogenix GmbH - AstraZeneca PLC - Axelar AB - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Celldex Therapeutics, Inc. - e-Therapeutics plc - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - ERC Belgium SA - GenSpera, Inc. - GlaxoSmithKline plc - GW Pharmaceuticals plc - ImmunoCellular Therapeutics, Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoEthix SA - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Sangamo BioSciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Tocagen Inc. - Vascular Biogenics Ltd. - Virttu Biologics Limited - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/ht3nzs/recurrent
ZIOP: 11.17 (+0.69), PFE: 34.36 (+0.50), CLDX: 24.89 (+0.42), SGMO: 9.86 (-0.02), AMGN: 154.10 (+2.79), SPPI: 7.08 (+0.05), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), IMUC: 0.49 (+0.01), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), VBLT: 6.19 (+0.32), KPTI: 25.57 (+0.24), NVS: 103.22 (+3.20)
Chagas Disease (American Trypanosomiasis) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 21 Drug Profiles
M2 - Wed Jun 10, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/llmftq/chagas_disease) has announced the addition of the "Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Grupo Praxis Pharmaceutical SA - Merck & Co., Inc. - Panacela Labs, Inc. - Sanofi - Seek Drug Profiles - benznidazol - chagas disease vaccine - Cz-007 - Cz-008 - Drugs for Chagas Disease - E-1224 - EPLBS-1246 - EPLBS-967 - fexinidazole - K-777 - LH-7 - Monoclonal Antibody for Chagas - NEU-321 - posaconazole - Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Small Molecules for Chagas Disease - Small Molecules for Infectious Diseases - Small Molecules for Protozoal Infections - Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - VNI - XELRYX-3 For more information visit http://www.researchandmarkets.com/research/ll...as_disease
MRK: 57.95 (+0.57), ANAC: 84.61 (+1.95)
Chemotherapy Induced Peripheral Neuropathy Therapeutics Pipeline Review, H1 2015 - 12 Companies & 16 Drug Profiles
M2 - Tue Jun 09, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9fr24c/chemotherapy) has announced the addition of the "Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - DARA BioSciences, Inc. - Eisai Co., Ltd. - Immune Pharmaceuticals, Ltd. - Laboratorios Del Dr. Esteve S.A. - MAKScientific, LLC - Mertiva AB - Paladin Labs Inc. - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Spectrum Pharmaceuticals, Inc. - Spinifex Pharmaceuticals Pty Limited - Virobay Inc. Drug Profiles - (amitriptyline ketamine hydrochloride) - AK-295 - AL-309 - AM-1710 - E-2072 - E-52862 - EMA-401 - Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - KRN-5500 - LM11A-31 - PAN-811 - PGN-703 - Small Molecule for Chemotherapy Induced Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - SPI-205 - VBY-036 For more information visit http://www.researchandmarkets.com/research/9f...emotherapy
SPPI: 7.08 (+0.05), IMNP: 1.88 (+0.04), VBAY: ()
Functional (Non Ulcer) Dyspepsia Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxkxp9/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Eisai Co., Ltd. - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. - Rottapharm SpA - Zeria Pharmaceutical Co Ltd Drug Profiles - 5-BOIP - acotiamide hydrochloride - cinitapride - dexloxiglumide - IW-9179 - rabeprazole sodium DR - RQ-00000010 - RQ-00201894 For more information visit http://www.researchandmarkets.com/research/zx...tional_non
IRWD: 11.44 (-0.06)
Synovial Sarcoma Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hxq4ts/synovial_sarcoma) has announced the addition of the "Synovial Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adaptimmune Limited - Eisai Co., Ltd. - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Novartis AG - OncoTherapy Science, Inc. Drug Profiles - Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - E-7438 - everolimus - OTSA-101 - pembrolizumab - selinexor - SSTC-104 For more information visit http://www.researchandmarkets.com/research/hx...al_sarcoma
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Down Syndrome Pipeline Review, H1 2015 - 5 Companies & 12 Drug Profiles
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t5gmd6/down_syndrome) has announced the addition of the "Down Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - NeuroNascent, Inc. - Transition Therapeutics Inc. Drug Profiles - ACI-24 - APH-1104 - AVL-8168 - BTD-001 - donepezil hydrochloride - ELND-005 - minocycline - NNI-351 - RG-1662 - Small Molecule DYRK1A Inhibitor for CNS Diseases - Small Molecules for Down Syndrome - Small Molecules to Inhibit OLIG2 for Down Syndrome For more information visit http://www.researchandmarkets.com/research/t5...n_syndrome
TTHI: 2.04 (+0.09)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 69.27 (+1.38), RGDO: 1.21 (unch)
Global Papillary Thyroid Cancer Therapeutics Pipeline Review, H1 2015 - 8 Companies & 13 Drug Profiles
M2 - Fri Jun 05, 6:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbchgs/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eisai Co., Ltd. - Exelixis, Inc. - Ignyta, Inc. - Novartis AG - Pfizer Inc. - Plexxikon Inc. - Vaccinex, Inc. Drug Profiles - cabozantinib s-malate - CLM-29 - CLM-3 - dabrafenib mesylate - entrectinib - everolimus - lenvatinib - pasireotide - PLX-7486 - PLX-8394 - sunitinib malate - vandetanib - VX-15 For more information visit http://www.researchandmarkets.com/research/fb...ry_thyroid
RXDX: 15.42 (+0.25), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Pipeline Review, H1 2015 - 14 Companies & 16 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lkxhm/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Anthera Pharmaceuticals Inc. - Azano Pharmaceuticals Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eisai Co., Ltd. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Pfizer Inc. - PhytoHealth Corporation - Rigel Pharmaceuticals, Inc. - SuppreMol GmbH Drug Profiles - Antibody for Autoimmune Disorders and Inflammation - avatrombopag - AZ-175 - belimumab - BI-655064 - blisibimod - BMS-986004 - eltrombopag olamine - fostamatinib disodium - GL-2045 - GSK-2285921 - HL-161 - MK-8723 - PHN-013 - SM-101 - veltuzumab For more information visit http://www.researchandmarkets.com/research/7lkxhm/idiopathic
IMMU: 4.20 (+0.24), ANTH: 8.32 (+0.85), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), RIGL: 3.11 (+0.10), MNTA: 21.76 (+0.49)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qwcpw/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agios Pharmaceuticals, Inc. - Amgen Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Conkwest, Inc. - Cornerstone Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Fujifilm Corporation - GlaxoSmithKline plc - Igenica Biotherapeutics, Inc. - Incyte Corporation - Jiangsu Hansoh Pharmaceutical Co., Ltd. - JW Pharmaceutical Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG For more information visit http://www.researchandmarkets.com/research/7q...psed_acute
EPZM: 23.42 (+0.45), CTIC: 1.91 (+0.03), ABBV: 69.23 (+1.26), EXEL: 3.68 (+0.25), MGNX: 38.85 (+3.03), INCY: 108.33 (+0.22), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ATNM: 2.41 (+0.18), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), CALA: 6.77 (unch), AVEO: 1.57 (unch), AGIO: 109.82 (+2.33), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Global Peripheral T-Cell Lymphomas (PTCL) Pipeline Review 2015
M2 - Wed Jun 03, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d57tr7/peripheral_tcell) has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Affimed Therapeutics AG - Bayer AG - Celgene Corporation - Eisai Co., Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - Mundipharma International Limited - Onxeo SA - Sanofi - Solasia Pharma K.K. - Spectrum Pharmaceuticals, Inc. - TG Therapeutics, Inc. Drug Profiles - AFM-13 - alemtuzumab - alisertib - belinostat - copanlisib - darinaparsin - denileukin diftitox - forodesine hydrochloride - lenalidomide - masitinib - mogamulizumab - pralatrexate - romidepsin - ruxolitinib phosphate - selinexor - SH-7129 - TGR-1202 For more information visit http://www.researchandmarkets.com/research/d5...eral_tcell
INCY: 108.33 (+0.22), TGTX: 18.21 (+0.08), SPPI: 7.08 (+0.05), KPTI: 25.57 (+0.24), CELGZ: 2.15 (+0.14)
Arterial Thrombosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/24q755/arterial) has announced the addition of the "Arterial Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Arterial Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arterial Thrombosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - Sanofi Drug Profiles - AS-1468240 - ASP-1645 - ASP-6537 - BAY-1213790 - BMS-593214 - C-3 - E-5539 - ER-410660 - Ichorcumab - PZ-128 - SAR-216471 - Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - temanogrel hydrochloride - ticagrelor For more information visit http://www.researchandmarkets.com/research/24q755/arterial
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38), ARNA: 4.29 (+0.04)
